NZ332404A - use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease - Google Patents

use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease

Info

Publication number
NZ332404A
NZ332404A NZ332404A NZ33240495A NZ332404A NZ 332404 A NZ332404 A NZ 332404A NZ 332404 A NZ332404 A NZ 332404A NZ 33240495 A NZ33240495 A NZ 33240495A NZ 332404 A NZ332404 A NZ 332404A
Authority
NZ
New Zealand
Prior art keywords
polypeptide
alginate
encapsulated
controlled release
inflammatory bowel
Prior art date
Application number
NZ332404A
Inventor
Wayne Richard Gombotz
Siuowfong Wee
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from NZ288997A external-priority patent/NZ288997A/en
Publication of NZ332404A publication Critical patent/NZ332404A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A polypeptide being either tumour necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R), interleukin-1 receptor antagonist (IL-1ra) or interleukin-6 receptor (IL-6R) or a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL-1is used in the manufacture of a medicament to treat inflammatory bowel disease. The medicament is in the form of a controlled release formulation and the polypeptide is encapsulated in alginate.
NZ332404A 1994-06-24 1995-06-22 use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease NZ332404A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26558794A 1994-06-24 1994-06-24
NZ288997A NZ288997A (en) 1994-06-24 1995-06-22 Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate

Publications (1)

Publication Number Publication Date
NZ332404A true NZ332404A (en) 2000-09-29

Family

ID=26651630

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332404A NZ332404A (en) 1994-06-24 1995-06-22 use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease

Country Status (1)

Country Link
NZ (1) NZ332404A (en)

Similar Documents

Publication Publication Date Title
Pantschenko et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression
McGee et al. A synergistic relationship between TNF-alpha, IL-1 beta, and TGF-beta 1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line.
Fujioka et al. Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteria-induced fulminant hepatitis in mice
Feldmann et al. The role of TNFα and IL-1 in rheumatoid arthritis
HK1020011A1 (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease
Tilg et al. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
Rose-John et al. Soluble receptors for cytokines and growth factors: generation and biological function.
Guirao et al. Biologic control of injury and inflammation: much more than too little or too late
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
Kabir et al. Serum levels of interleukin-1, interleukin-6 and tumour necrosis factor-alpha in patients with gastric carcinoma
EP2364731A3 (en) Methods of administering anti-TNFalpha antibodies
DE69724451D1 (en) COMBINATION THERAPY WITH A TNF-BINDING PROTEIN FOR TREATING DISEASES CAUSED BY TNF
Yamada et al. Intravenous immunoglobulin treatment in women with recurrent abortions: increased cytokine levels and reduced Th1/Th2 lymphocyte ratio in peripheral blood
PT689449E (en) COMPOSITIONS FOR APPLICATION IN HUMAN THERAPEUTICS CHARACTERIZED BY THE ASSOCIATION OF A MURAMILO PEPTIDE TO A CITOQUIN
EP0770680A3 (en) Lymphocyte-associated cell surface protein
Hansen et al. Influence of interleukin‐6 (IL‐6) autoantibodies on IL‐6 binding to cellular receptors
Tokayer et al. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
McGee et al. The effect of cytokine stimulation on IL-1 receptor mRNA expression by intestinal epithelial cells
Pirhonen Regulation of IL‐18 expression in virus infection
EP1206274B1 (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
NZ332404A (en) use of a controlled release formulation containing a polypeptide such as IL-6R encapsulated in alginate for treating inflammatory bowel disease
Lentz The role of therapeutic apheresis in the treatment of cancer: a review
EP1225915A4 (en) Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
Porreca et al. Effect of interleukin-1 receptor antagonist on vascular smooth muscle cell proliferation
MX9606550A (en) Controlled release polypeptide compositions and methods of treating inflammatory bowel disease.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired